New Zealand Markets closed

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3141-0.0292 (-8.51%)
At close: 04:00PM EDT
0.3148 +0.00 (+0.22%)
After hours: 07:17PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.05
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 32.7700
52-week low 30.3000
50-day moving average 30.5776
200-day moving average 31.0994

Share statistics

Avg vol (3-month) 31.62M
Avg vol (10-day) 3355.69k
Shares outstanding 525.97M
Implied shares outstanding 6N/A
Float 817.92M
% held by insiders 140.26%
% held by institutions 110.18%
Shares short (30 Jan 2023) 4654.29k
Short ratio (30 Jan 2023) 40.27
Short % of float (30 Jan 2023) 42.67%
Short % of shares outstanding (30 Jan 2023) 42.52%
Shares short (prior month 29 Dec 2022) 495.92k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-1,086.39%

Management effectiveness

Return on assets (ttm)-101.84%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)2.87M
Revenue per share (ttm)0.17
Quarterly revenue growth (yoy)-22.50%
Gross profit (ttm)-35.4M
EBITDA -30.58M
Net income avi to common (ttm)-32.79M
Diluted EPS (ttm)-2.4360
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.89M
Total cash per share (mrq)0.09
Total debt (mrq)14.08M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.20
Book value per share (mrq)-0.86

Cash flow statement

Operating cash flow (ttm)-24.3M
Levered free cash flow (ttm)-14.19M